Sitagliptin and Metformin Immediate-Release Coadministration in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise Table 1 summarizes the most common (5% of patients) adverse reactions reported (regardless of investigator assessment of causality) in a 24-week placebo-controlled factorial study in which sitagliptin and metformin immediate-release were coadministered to patients with type 2 diabetes inadequately controlled on diet and exercise
To address the issue they performed transfusion experiments with dogs where they connected the pancreatic vein of a donor dog to the jugular vein of a recipient dog and then injected secretin extracts
In the PIONEER programme [35,36,37,38,39,40,41,42], the most frequent adverse events were nausea and diarrhoea, which are common side effects of GLP-1 analogues
Weekly check-ins on appetite suppression, gastrointestinal tolerance, and early weight changes help inform the pace of titration
Look for exact ingredient amounts, not just proprietary blends. Lack of dosage transparency is a red flag
Risks to Watch : Dehydration, hypoglycemia (when combined with insulin), and interactions with other medications
